EGFR has been considered to be a receptor involved in cervical cancer progression (4,5), however, clinical trials are still not conclusive as to whether blocking EGFR is effective enough for justifying its use in the clinical setting (9–11). This evidence concerns the gene EGFR and cervical carcinoma.